Fig. 4From: Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)A Overall survival and B progression-free survival by hypogammaglobulinemia resolving status in patients with PR or better. Ig Immunoglobulin, PR partial responseBack to article page